XOMA Royalty and LAVA Therapeutics Reveal Changes to Purchase Agreement

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Oct 17 2025

0mins

Source: Globenewswire

Amendment Details: LAVA Therapeutics and XOMA Royalty Corporation have amended their share purchase agreement, reducing the initial cash amount per share to $1.04 and updating the contingent value rights (CVR) terms, including a new right to receive additional cash based on potential liabilities.
Extended Offer Timeline: The tender offer for LAVA shares has been extended to November 12, 2025, with the acquisition expected to close in the fourth quarter of 2025, pending customary closing conditions and shareholder approvals.
Extraordinary General Meeting: LAVA will reconvene its Extraordinary General Meeting of Shareholders on November 7, 2025, to approve resolutions related to the transactions with XOMA Royalty, which were previously scheduled for September 30, 2025.
Forward-Looking Statements: Both companies have issued cautionary notes regarding forward-looking statements, highlighting potential risks and uncertainties that could affect the completion and benefits of the transactions.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free